

## PerCP/Cyanine5.5 anti-mouse CD45 Antibody

<b>Catalog# / Size</b>	103131 / 25 µg 103132 / 100 µg
<b>Clone</b>	30-F11
<b>Regulatory Status</b>	RUO
<b>Other Names</b>	T200, Ly-5, LCA
<b>Isotype</b>	Rat IgG2b, κ
<b>Description</b>	CD45 is a 180-240 kD glycoprotein also known as the leukocyte common antigen (LCA), T200, or Ly-5. It is a member of the protein tyrosine phosphatase (PTP) family, expressed on all hematopoietic cells except mature erythrocytes and platelets. There are different isoforms of CD45 that arise from variable splicing of exons 4, 5, and 6, which encode A, B, and C determinants, respectively. CD45 plays a key role in TCR and BCR signal transduction. These isoforms are very specific to the activation and maturation state of the cell as well as cell type. The primary ligands for CD45 are galectin-1, CD2, CD3, CD4, TCR, CD22, and Thy-1.

### Product Details

<b>Verified Reactivity</b>	Mouse
<b>Antibody Type</b>	Monoclonal
<b>Host Species</b>	Rat
<b>Immunogen</b>	Mouse thymus or spleen
<b>Formulation</b>	Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
<b>Preparation</b>	The antibody was purified by affinity chromatography, and conjugated with PerCP/Cyanine5.5 under optimal conditions.
<b>Concentration</b>	0.2 mg/ml
<b>Storage &amp; Handling</b>	The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. <b>Do not freeze.</b>
<b>Application</b>	<a href="#">FC - Quality tested</a>
<b>Recommended Usage</b>	Each lot of this antibody is quality control tested by <a href="#">immunofluorescent staining with flow cytometric analysis</a> . For flow cytometric staining, the suggested use of this reagent is = 0.25 µg per 10 <sup>6</sup> cells in 100 µl volume. It is recommended that the reagent be titrated for optimal performance for each application.  * PerCP/Cyanine5.5 has a maximum absorption of 482 nm and a maximum emission of 690 nm.
<b>Excitation Laser</b>	Blue Laser (488 nm)
<b>Application Notes</b>	Clone 30-F11 reacts with all isoforms and both CD45.1 and CD45.2 alloantigens of CD45.  Additional reported applications (for relevant formats) include: immunoprecipitation <sup>3</sup> , complement-dependent cytotoxicity <sup>1,5</sup> , immunohistochemistry (acetone-fixed frozen sections, zinc-fixed paraffin-embedded sections and formalin-fixed paraffin-embedded sections) <sup>4,6</sup> , Western blotting <sup>7</sup> , and spatial biology (IBEX) <sup>10,11</sup> . The Ultra-LEAF™ purified antibody (Endotoxin < 0.01 EU/µg, Azide-Free, 0.2 µm filtered) is recommended for functional assays (Cat. No. 103163 and 103164).
<b>Additional Product Notes</b>	BioLegend is in the process of converting the name PerCP/Cy5.5 to PerCP/Cyanine5.5. The dye molecule remains the same, so you should expect the same quality and performance from our PerCP/Cyanine5.5 products. Contact <a href="#">Technical Service</a> if you have any questions.
<b>Application References</b>	<ol style="list-style-type: none"> <li>1. Podd BS, <i>et al.</i> 2006. <i>J. Immunol.</i> 176:6532. (FC, CMCD) <a href="#">PubMed</a></li> <li>2. Haynes NM, <i>et al.</i> 2007. <i>J. Immunol.</i> 179:5099. (FC)</li> <li>3. Ledbetter JA, <i>et al.</i> 1979. <i>Immunol. Rev.</i> 47:63. (IP)</li> </ol>

4. Simon DI, *et al.* 2000. *J. Clin. Invest.* 105:293. (IHC)
5. Seaman WE. 1983. *J. Immunol.* 130:1713. (CMCD)
6. Cornet A, *et al.* 2001. *P. Natl. Acad. Sci. USA* 98:13306. (IHC)
7. Tsuboi S and Fukuda M. 1998. *J. Biol. Chem.* 273:30680. (WB) [PubMed](#)
8. Liu F, *et al.* 2012. *Blood.* 119:3295. [PubMed](#)
9. Pelletier AN, *et al.* 2012. *J. Immunol.* 188:5561. [PubMed](#)
10. Radtke AJ, *et al.* 2020. *Proc Natl Acad Sci U S A.* 117:33455-65. (SB) [PubMed](#)
11. Radtke AJ, *et al.* 2022. *Nat Protoc.* 17:378-401. (SB) [PubMed](#)

## Product Citations

1. Choi JG, *et al.* 2020. *Front Immunol.* 11:598556. [PubMed](#)
2. Gogoi H, *et al.* 2020. *Front Immunol.* 11:620833333. [PubMed](#)
3. Daemen S, *et al.* 2021. *Cell Reports.* 34(2):108626. [PubMed](#)
4. Zaman R, *et al.* 2021. *Immunity.* .: [PubMed](#)
5. Ramakrishna C, *et al.* 2019. *Nat Commun.* 10:2153. [PubMed](#)
6. Shah D, *et al.* 2021. *Oncoimmunology.* 10:1939601. [PubMed](#)
7. Xiang G, *et al.* 2022. *Cell Death Dis.* 13:451. [PubMed](#)
8. Pani F, *et al.* 2021. *Endocrinology.* 162:. [PubMed](#)
9. Xiong W, *et al.* 2022. *Nat Commun.* 13:1700. [PubMed](#)
10. Tan L, *et al.* 2022. *Aging Dis.* 13:1562. [PubMed](#)
11. Jung IY, *et al.* 2022. *Sci Transl Med.* 14:eabn7336. [PubMed](#)
12. Krausgruber T, *et al.* 2020. *Nature.* 583:296. [PubMed](#)
13. Kawano H, *et al.* 2016. *Int Immunol.* 28: 489 - 501. [PubMed](#)
14. Liu W, *et al.* 2020. *Mol Ther Oncolytics.* 17:350. [PubMed](#)
15. Yang H, *et al.* 2019. *Mol Metab.* 23:24. [PubMed](#)
16. Alissafi T, *et al.* 2018. *J Clin Invest.* 128:3840. [PubMed](#)
17. Tan L, *et al.* 2022. *Biochem Biophys Rep.* 32:101351. [PubMed](#)
18. Padonou F, *et al.* 2022. *EMBO Rep.* 23:e53576. [PubMed](#)
19. Golden GJ, *et al.* 2021. *MBio.* 12:e0118121. [PubMed](#)
20. Taddeo A, *et al.* 2022. *NPJ Vaccines.* 7:82. [PubMed](#)
21. Li Y, *et al.* 2022. *Int J Biol Sci.* 18:3697. [PubMed](#)
22. Tatsuguchi T, *et al.* 2022. *Int Immunol.* 34:277. [PubMed](#)
23. Li Z, *et al.* 2021. *Immunology.* 163:105. [PubMed](#)
24. Browning D, *et al.* 2017. *Gene Ther.* 10.1038/gt.2016.88. [PubMed](#)
25. Rodda LB *et al.* 2018. *Immunity.* 48(5):1014-1028 . [PubMed](#)
26. Barry KC, *et al.* 2018. *Nat Med.* 24:1178. [PubMed](#)
27. Hsu SPC, *et al.* 2020. *J Neurooncol.* 146:417. [PubMed](#)
28. Yang M, *et al.* 2020. *Cell Prolif.* 53:e12784. [PubMed](#)
29. Hanhai Z, *et al.* 2021. *Aging (Albany NY).* 13:13108. [PubMed](#)
30. Song J, *et al.* 2021. *J Am Heart Assoc.* 10:e017329. [PubMed](#)
31. Sasse C, *et al.* 2022. *Pathogens.* 11:. [PubMed](#)
32. Coleby R, *et al.* 2021. *Clin Exp Rheumatol.* :39. [PubMed](#)
33. Garcia-Agudo LF, *et al.* 2019. *FASEB J.* :fj201900337R. [PubMed](#)
34. Zaytseva D, *et al.* 2018. *Physiol Rep.* 6:e13812. [PubMed](#)
35. Schmidleithner L *et al.* 2019. *Immunity.* 50(5):1232-1248 . [PubMed](#)
36. Biffi G, *et al.* 2018. *Cancer Discov.* 2:282. [PubMed](#)
37. Jazowiecka-Rakus J, *et al.* 2021. *Cancers (Basel).* 13:. [PubMed](#)
38. Ren J, *et al.* 2021. *Theranostics.* 11:304. [PubMed](#)
39. Craver BM, *et al.* 2020. *Blood Adv.* 4:312. [PubMed](#)
40. Chen M, *et al.* 2021. *Cancers (Basel).* 13:. [PubMed](#)
41. Peng Z, *et al.* 2021. *STAR Protocols.* 2(2):100595. [PubMed](#)
42. Jeong D, *et al.* 2021. *eLife.* 0.4166666666666667. [PubMed](#)
43. Pan H, *et al.* 2020. *Mol Psychiatry.* . [PubMed](#)
44. Damal Villivalam S, *et al.* 2020. *Nat Commun.* 4313:11. [PubMed](#)
45. Chaurasiya S, *et al.* 2020. *Oncoimmunology.* 9:1729300. [PubMed](#)
46. Somerville TD, *et al.* 2020. *eLife.* 9:e53381. [PubMed](#)
47. Zhong J, *et al.* 2018. *Sci Adv.* 4:eaas9864. [PubMed](#)
48. Helm M, *et al.* 2022. *Life (Basel).* 12:. [PubMed](#)
49. Potluri HK, *et al.* 2022. *J Immunother Cancer.* 10:. [PubMed](#)
50. Papafragkos I, *et al.* 2022. *Front Immunol.* 13:889075. [PubMed](#)
51. Liang Z, *et al.* 2021. *J Cell Physiol.* 236:4725. [PubMed](#)
52. Fernandez Garcia-Agudo L, *et al.* 2021. *Cell Rep.* 36:109548. [PubMed](#)
53. Chung H, *et al.* 2021. *Immune Netw.* 21:e28. [PubMed](#)
54. Shen H, *et al.* 2022. *Nat Commun.* 13:6030. [PubMed](#)
55. Wang C, *et al.* 2021. *Cell Stem Cell.* . [PubMed](#)
56. Fachi JL, *et al.* 2020. *J Exp Med.* 217:00:00. [PubMed](#)
57. Sakaguchi M, *et al.* 2022. *Nat Commun.* 13:6092. [PubMed](#)
58. Chimenti I, *et al.* 2022. *Cell Death Discov.* 8:149. [PubMed](#)
59. Liu Y, *et al.* 2022. *Nat Commun.* 13:2665. [PubMed](#)
60. Vijay R, *et al.* 2015. *J Exp Med.* 212: 1851 - 1868. [PubMed](#)
61. Fleury M, *et al.* 2015. *Development.* 142: 3307 - 3320. [PubMed](#)
62. Osborne JK, *et al.* 2021. *Cell Reports.* 36(3):109408. [PubMed](#)
63. Wei SC, *et al.* 2020. *Cancer Discov.* . [PubMed](#)
64. Vasilijevic J, *et al.* 2017. *PLoS Pathog.* 13:e1006650. [PubMed](#)
65. Caronni N, *et al.* 2018. *Cancer Res.* 78:1685. [PubMed](#)
66. Zhang D, *et al.* 2020. *Signal Transduct Target Ther.* 5:24. [PubMed](#)
67. Alexander RK, *et al.* 2020. *eLife.* 9:e54090. [PubMed](#)
68. Voisin M, *et al.* 2021. *Commun Biol.* 4:420. [PubMed](#)
69. Edwards CJ, *et al.* 2021. *Br J Cancer.* . [PubMed](#)

70. Peres-Emidio EC, *et al.* 2022. *Front Cell Infect Microbiol.* 12:811474. [PubMed](#)
71. Cong M, *et al.* 2021. *Methods Mol Biol.* 2388:59. [PubMed](#)
72. Frii J, *et al.* 2021. *Immunity.* 54(5):1002-1021.e10. [PubMed](#)
73. Nicholas DA, *et al.* 2020. *Scientific Reports.* 10(1):13063. [PubMed](#)
74. Deng Z, *et al.* 2017. *Oncogene.* 36:639. [PubMed](#)
75. Linde N, *et al.* 2018. *Nat Commun.* 9:21. [PubMed](#)
76. Wang W, *et al.* 2022. *Aging Cell.* 21:e13630. [PubMed](#)
77. Lee J, *et al.* 2022. *Nat Commun.* 13:1516. [PubMed](#)
78. Mansouri S, *et al.* 2021. *J Immunol.* 206:2233. [PubMed](#)
79. Li Z, *et al.* 2022. *J Exp Clin Cancer Res.* 41:74. [PubMed](#)
80. Mencarelli A, *et al.* 2016. *Sci Rep.* 6:30802. [PubMed](#)
81. Li N, *et al.* 2021. *eLife.* 10:00. [PubMed](#)
82. Zhao J, *et al.* 2018. *Stem Cell Reports.* 10:180. [PubMed](#)
83. Wu Y, *et al.* 2021. *Nat Commun.* 12:2346. [PubMed](#)
84. Shi R, *et al.* 2022. *Theranostics.* 12:875. [PubMed](#)
85. Akazawa S, *et al.* 2021. *Diabetologia.* 64:878. [PubMed](#)
86. Formaglio P, *et al.* 2021. *Immunity.* 54:2724. [PubMed](#)
87. Grune J, *et al.* 2022. *Nat Cardiovasc Res.* 1:649. [PubMed](#)
88. Witkowski MT, *et al.* 2020. *Cancer Cell.* 37:867. [PubMed](#)
89. Hu Y, *et al.* 2021. *Bioact Mater.* 2905:6. [PubMed](#)
90. Wen Y, *et al.* 2020. *Hypertension.* 869:75. [PubMed](#)
91. Hsu CY, *et al.* 2020. *Frontiers in Immunology.* 11:574839. [PubMed](#)
92. Bayik D, *et al.* 2020. *Cancer Discov.* 1.256944444. [PubMed](#)
93. Horiguchi H, *et al.* 2019. *Genes Dev.* 33:1641. [PubMed](#)
94. Adrover JM *et al.* 2019. *Immunity.* 50(2):390-402. [PubMed](#)
95. Christ A, *et al.* 2018. *Cell.* 172:162. [PubMed](#)
96. Hepler C *et al.* 2018. *eLife.* 7 pii: e39636. [PubMed](#)
97. Yang J, *et al.* 2022. *Microbiome.* 10:149. [PubMed](#)
98. Goldfarb Y, *et al.* 2021. *J Exp Med.* 218:. [PubMed](#)
99. Yang Z, *et al.* 2021. *Sci Adv.* 7:. [PubMed](#)
100. Zeng Q, *et al.* 2022. *Front Immunol.* 13:740805. [PubMed](#)
101. Myerson JW, *et al.* 2021. *Nat Nanotechnol.* Online ahead of print. [PubMed](#)
102. Liu Z, *et al.* 2015. *Development.* 142: 2452 - 2463. [PubMed](#)
103. Wang Y, *et al.* 2020. *Cell Death Dis.* 1.169444444. [PubMed](#)
104. Sharma M, *et al.* 2020. *Circ Res.* 127:335. [PubMed](#)
105. Shao M, *et al.* 2021. *Cell Stem Cell.* 28(4):685-701.e7. [PubMed](#)
106. Xiang W, *et al.* 2018. *Nat Commun.* 9:2574. [PubMed](#)
107. Du Q *et al.* 2019. *Dev Cell.* 49(4):618-631. [PubMed](#)
108. Branchett WJ, *et al.* 2020. *Wellcome Open Research.* 0.278472222. [PubMed](#)
109. Shannon JP, *et al.* 2021. *STAR Protoc.* 2:100790. [PubMed](#)
110. Krueger A, *et al.* 2022. *Front Microbiol.* 12:789042. [PubMed](#)
111. Mittal A, *et al.* 2021. *Sci Rep.* 11:10731. [PubMed](#)
112. Germundson DL, *et al.* 2022. *Front Allergy.* 3:870513. [PubMed](#)
113. Weinstock A, *et al.* 2021. *Elife.* :10. [PubMed](#)
114. Joffin N, *et al.* 2021. *Cell Stem Cell.* 28(4):702-717.e8. [PubMed](#)
115. Shannon JP, *et al.* 2021. *Immunity.* 54(2):276-290.e5. [PubMed](#)
116. Ballesteros I, *et al.* 2020. *Cell.* 183(5):1282-1297.e18. [PubMed](#)
117. Alonso-Herranz L, *et al.* 2020. *Elife.* 9:00. [PubMed](#)
118. Sun L, *et al.* 2015. *Sci Rep.* 5: 14871. [PubMed](#)
119. Timblin GA, *et al.* 2021. *Nat Metab.* 3:618. [PubMed](#)
120. Otvos B, *et al.* 2021. *Clin Cancer Res.* 27:2038. [PubMed](#)
121. Lang V, *et al.* 2021. *Elife.* 10:. [PubMed](#)
122. Toth K, *et al.* 2022. *PLoS Biol.* 20:e3001526. [PubMed](#)
123. Chandra J, *et al.* 2016. *Immunol Cell Biol.* 10.1038/icb.2016.83. [PubMed](#)
124. Uematsu T, *et al.* 2016. *Sci Rep.* 6:37815. [PubMed](#)
125. Alam Z, *et al.* 2020. *Cell Rep.* 107825:31. [PubMed](#)
126. Gubin MM, *et al.* 2018. *Cell.* 175:1014. [PubMed](#)
127. Li CJ, *et al.* 2018. *J Clin Invest.* 128:5251. [PubMed](#)
128. Tao Z, *et al.* 2019. *Clin Cancer Res.* 25:1113. [PubMed](#)
129. Zhang Q, *et al.* 2021. *Front Cell Dev Biol.* 9:655552. [PubMed](#)
130. Tuong ZK, *et al.* 2021. *iScience.* 24:103326. [PubMed](#)
131. Thomas K, *et al.* 2022. *JCI Insight.* :. [PubMed](#)
132. Xu X, *et al.* 2022. *EMBO Rep.* 23:e53509. [PubMed](#)
133. Gomez S, *et al.* 2022. *J Immunother Cancer.* 10:. [PubMed](#)
134. Shan B, *et al.* 2020. *Nat Metab.* 1332:2. [PubMed](#)
135. Mansouri S, *et al.* 2020. *Mucosal Immunol.* 0.954861111. [PubMed](#)
136. Martomo SA, *et al.* 2021. *Mol Cancer Ther.* 1.074305556. [PubMed](#)
137. Kalafati L, *et al.* 2020. *Cell.* 183:771. [PubMed](#)
138. Ngamsri KC, *et al.* 2020. *Front Immunol.* 11:407. [PubMed](#)
139. Haider N, *et al.* 2020. *Cell Commun Signal.* 18:26. [PubMed](#)
140. Bernstock JD, *et al.* 2019. *J Allergy Clin Immunol.* 145:358. [PubMed](#)
141. Dahlgren MW *et al.* 2019. *Immunity.* 50(3):707-722. [PubMed](#)
142. Xu G, *et al.* 2022. *Front Pharmacol.* 13:896601. [PubMed](#)
143. Li M, *et al.* 2021. *Cancers (Basel).* 13:. [PubMed](#)
144. Dong X, *et al.* 2022. *Front Immunol.* 13:896472. [PubMed](#)
145. Pizzurro GA, *et al.* 2021. *Cancers (Basel).* 13:. [PubMed](#)
146. Olson B, *et al.* 2021. *Brain Behav Immun.* 97:102. [PubMed](#)
147. Calle P, *et al.* 2021. *Cells.* 10:. [PubMed](#)
148. Upadhyya R, *et al.* 2016. *MBio.* 7: 00547-16. [PubMed](#)
149. Yu M, *et al.* 2021. *Molecular Cell.* 81(6):1216-1230.e9. [PubMed](#)

150. Zhang H, *et al.* 2021. Cell Reports. 35(6):109096. [PubMed](#)
151. Ko HJ, *et al.* 2020. Front Immunol. 1897:11. [PubMed](#)
152. Klose A, *et al.* 2018. JCSM Rapid Commun. 9:20222. [PubMed](#)
153. Casanova-Acebes M, *et al.* 2018. J Exp Med. 215:2778. [PubMed](#)
154. Chiang N, *et al.* 2019. J Clin Invest. 129:5294. [PubMed](#)
155. Scott NA, *et al.* 2018. Front Immunol. 2.319444444. [PubMed](#)
156. Karolin A, *et al.* 2022. Front Pharmacol. 12:789080. [PubMed](#)
157. Jazowiecka-Rakus J, *et al.* 2020. Mol Ther Oncolytics. 18:335. [PubMed](#)
158. Wong NR, *et al.* 2021. Immunity. 54:2072. [PubMed](#)
159. Mesnieres M, *et al.* 2021. Cell Reports. 36(8):109618. [PubMed](#)
160. Doss PMIA, *et al.* 2021. Cell Reports. 34(10):108833. [PubMed](#)
161. Caporarello N, *et al.* 2020. Aging Cell. 19:e13196. [PubMed](#)
162. Huo M, *et al.* 2017. FASEB J. 10.1096/fj.201601030R. [PubMed](#)
163. Moufarrij S, *et al.* 2020. Sci Rep. 10:3470. [PubMed](#)
164. Böhm AM *et al.* 2019. Dev Cell. 51(2):236-254. [PubMed](#)
165. Clemente-Casares X, *et al.* 2017. Immunity. 47:974. [PubMed](#)
166. Mello AM, *et al.* 2022. Oncogenesis. 11:56. [PubMed](#)
167. Shaikh H, *et al.* 2021. Front Immunol. 12:689896. [PubMed](#)
168. Sánchez-del-Campo L, *et al.* 2021. J Exp Clin Cancer Res. 40:117. [PubMed](#)
169. Steele NG, *et al.* 2021. Clin Cancer Res. 27:2023. [PubMed](#)
170. Casselli T, *et al.* 2021. PLoS Pathog. 17:e1009256. [PubMed](#)
171. Patel K, *et al.* 2016. Mucosal Immunol. 10.1038/mi.2016.11. [PubMed](#)
172. Tsunekuni K, *et al.* 2020. J Clin Med. 9:00. [PubMed](#)
173. Yin X, *et al.* 2020. Cell Rep. 33:108278. [PubMed](#)
174. Zhang D, *et al.* 2020. Signal Transduct Target Ther. 5:24. [PubMed](#)
175. Chung S, *et al.* 2020. Am J Physiol Lung Cell Mol Physiol. L921:318. [PubMed](#)
176. Baron CS, *et al.* 2018. Nat Commun. 9:2517. [PubMed](#)
177. Gaya M *et al.* 2018. Cell. 172(3):517-533. [PubMed](#)
178. Miragaia RJ, *et al.* 2018. Sci Rep. 8:685. [PubMed](#)
179. Chen L, *et al.* 2021. Theranostics. 11:6668. [PubMed](#)
180. Sugita Y, *et al.* 2021. Oncol Rep. 45:. [PubMed](#)
181. Yu H, *et al.* 2021. Cell Death Dis. 13:1. [PubMed](#)
182. Wang R, *et al.* 2022. J Immunother Cancer. 10:. [PubMed](#)
183. Zhang Z, *et al.* 2020. Nature. 579:415. [PubMed](#)
184. Gong P, *et al.* 2022. Cell Death Discov. 8:466. [PubMed](#)
185. Liu SS, *et al.* 2021. Immunity. .: [PubMed](#)
186. Wang Y, *et al.* 2021. Nat Commun. 0.570833333. [PubMed](#)
187. Gao P, *et al.* 2020. Front Immunol. 1.636111111. [PubMed](#)
188. Sharma M, *et al.* 2019. Immunometabolism. 1. [PubMed](#)
189. Liang Z, *et al.* 2017. Autophagy. 14:505. [PubMed](#)
190. Rosen SF, *et al.* 2022. Genome Med. 14:108. [PubMed](#)
191. Schulze J, *et al.* 2021. Stroke. 52:2939. [PubMed](#)
192. Liu X, *et al.* 2021. Adv Sci (Weinh). 8:e2100233. [PubMed](#)
193. Garcia-Alegria E, *et al.* 2016. Sci Rep. 6: 25917. [PubMed](#)
194. Kim SI, *et al.* 2020. Molecular Cancer Therapeutics. 20(1):173-182. [PubMed](#)
195. Durga Devi T, *et al.* 2017. Am J Pathol. 187:2659. [PubMed](#)
196. Wang L, *et al.* 2020. Nat Commun. 0.654166667. [PubMed](#)
197. Hsu HP, *et al.* 2021. J Biol Chem. 296:100419. [PubMed](#)
198. Mansouri S, *et al.* 2021. J Immunol. 206:2233. [PubMed](#)
199. Chen Y, *et al.* 2021. Braz J Med Biol Res. 54:e9570. [PubMed](#)
200. Caporarello N, *et al.* 2022. Nat Commun. 13:4170. [PubMed](#)
201. Deptuch T, *et al.* 2022. Sci Rep. 12:13480. [PubMed](#)
202. Omori S, *et al.* 2020. Cell Metabolism. 32(5):814-828.e6. [PubMed](#)
203. Xiang W, *et al.* 2020. Signal Transduct Target Ther. 0.374305556. [PubMed](#)
204. Uematsu T, *et al.* 2015. Sci Rep. 5: 17577. [PubMed](#)
205. Mitchell LA, *et al.* 2019. Oncotarget. 10:2252. [PubMed](#)
206. Han Y, *et al.* 2019. J Clin Invest. 130:26. [PubMed](#)
207. Riopel M, *et al.* 2019. Mol Metab. 20:89. [PubMed](#)
208. Liang Z, *et al.* 2022. iScience. 25:105233. [PubMed](#)
209. Vogiatzi A, *et al.* 2021. Mol Cell Biol. 41:e0014921. [PubMed](#)
210. Song X, *et al.* 2022. Transl Oncol. 15:101306. [PubMed](#)
211. Li X, *et al.* 2021. Front Immunol. 12:779560. [PubMed](#)
212. Sheriff L, *et al.* 2020. Dis Model Mech. 13:dmm046383. [PubMed](#)
213. Zheng QY, *et al.* 2020. FASEB J. 34:10590. [PubMed](#)
214. Wirasinha RC, *et al.* 2021. J Exp Med. 218: . [PubMed](#)

## RRID

AB\_893344 (BioLegend Cat. No. 103131)  
 AB\_893340 (BioLegend Cat. No. 103132)

## Antigen Details

---

<b>Structure</b>	Protein tyrosine phosphatase (PTP) family, 180-240 kD
<b>Distribution</b>	All hematopoietic cells except mature erythrocytes and platelets
<b>Function</b>	Phosphatase, T and B cell activation

<b>Ligand/Receptor</b>	Galectin-1, CD2, CD3, CD4, TCR, CD22, Thy-1
<b>Cell Type</b>	B cells, Dendritic cells, Mesenchymal Stem Cells, Tregs
<b>Biology Area</b>	Cell Biology, Immunology, Inhibitory Molecules, Innate Immunity, Neuroscience, Neuroscience Cell Markers, Stem Cells
<b>Molecular Family</b>	CD Molecules
<b>Antigen References</b>	<ol style="list-style-type: none"> <li>1. Barclay A, <i>et al.</i> 1997. The Leukocyte Antigen FactsBook Academic Press.</li> <li>2. Trowbridge IS, <i>et al.</i> 1993. <i>Annu. Rev. Immunol.</i> 12:85.</li> <li>3. Kishihara K, <i>et al.</i> 1993. <i>Cell</i> 74:143.</li> <li>4. Pulido R, <i>et al.</i> 1988. <i>J. Immunol.</i> 140:3851.</li> </ol>
<b>Gene ID</b>	<a href="#">19264</a>


## Related Protocols

[Cell Surface Flow Cytometry Staining Protocol](#)

## Other Formats

APC anti-mouse CD45, Biotin anti-mouse CD45, FITC anti-mouse CD45, PE anti-mouse CD45, PE/Cyanine5 anti-mouse CD45, Purified anti-mouse CD45, PE/Cyanine7 anti-mouse CD45, APC/Cyanine7 anti-mouse CD45, Alexa Fluor® 488 anti-mouse CD45, Alexa Fluor® 647 anti-mouse CD45, Pacific Blue™ anti-mouse CD45, Alexa Fluor® 700 anti-mouse CD45, PerCP/Cyanine5.5 anti-mouse CD45, PerCP anti-mouse CD45, Alexa Fluor® 594 anti-mouse CD45, Brilliant Violet 421™ anti-mouse CD45, Brilliant Violet 570™ anti-mouse CD45, Brilliant Violet 510™ anti-mouse CD45, Brilliant Violet 605™ anti-mouse CD45, Purified anti-mouse CD45 (Maxpar® Ready), PE/Dazzle™ 594 anti-mouse CD45, Brilliant Violet 711™ anti-mouse CD45, Brilliant Violet 785™ anti-mouse CD45, Brilliant Violet 650™ anti-mouse CD45, APC/Fire™ 750 anti-mouse CD45, Brilliant Violet 750™ anti-mouse CD45, TotalSeq™-A0096 anti-mouse CD45, TotalSeq™-B0096 anti-mouse CD45, Ultra-LEAF™ Purified anti-mouse CD45, Spark Blue™ 550 anti-mouse CD45, Spark NIR™ 685 anti-mouse CD45, TotalSeq™-C0096 anti-mouse CD45, Spark YG™ 570 anti-mouse CD45, PE/Fire™ 640 anti-mouse CD45, APC/Fire™ 810 anti-mouse CD45, PE/Fire™ 700 anti-mouse CD45, Spark Violet™ 538 anti-mouse CD45, Spark YG™ 593 anti-mouse CD45, Spark Blue™ 574 anti-mouse CD45 Antibody

## Product Data



C57BL/6 mouse splenocytes were stained with CD45 (Clone 30-F11) PerCP/Cyanine5.5 (filled histogram), or rat IgG2b, ? PerCP/Cyanine5.5 isotype control (open histogram).

For research use only. Not for diagnostic use. Not for resale. BioLegend will not be held responsible for patent infringement or other violations that may occur with the use of our products.

\*These products may be covered by one or more Limited Use Label Licenses (see the BioLegend Catalog or our website, [www.biolegend.com/ordering#license](http://www.biolegend.com/ordering#license)). BioLegend products may not be transferred to third parties, resold, modified for resale, or used to manufacture commercial products, reverse engineer functionally similar materials, or to provide a service to third parties without written approval of BioLegend. By use of these products you accept the terms and conditions of all applicable Limited Use Label Licenses. Unless otherwise indicated, these products are for research use only and are not intended for human or animal diagnostic, therapeutic or commercial use.

BioLegend Inc., 8999 BioLegend Way, San Diego, CA 92121 [www.biolegend.com](http://www.biolegend.com)  
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587